Skip to main content
رجوع
MLYS logo

Mineralys Therapeutics, Inc.

جودة البيانات: 100%
ذروة بيع
MLYS
NASDAQ Healthcare Biotechnology
KWD 22.88
▼ KWD 0.77 (-3.26%)
القيمة السوقية: 1.52B
نطاق اليوم
KWD 22.42 KWD 23.87
نطاق 52 أسبوعًا
KWD 10.44 KWD 47.65
حجم التداول
784,570
متوسط 50 يوم / 200 يوم
KWD 29.55 / KWD 29.16
الإغلاق السابق
KWD 23.65

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -9.8 0.3
P/B 2.4 2.9
ROE % -36.9 3.7
Net Margin % 3.8
Rev Growth 5Y % 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 46.000 +101.0%
Low: KWD 30.000 High: KWD 56.000
ربحية السهم المستقبلية
-KWD 2.192
الإيرادات المقدّرة
560000

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 5.233
KWD 2.668 – KWD 13.203
1.3 B 1
FY2029 KWD 2.475
KWD 1.262 – KWD 6.245
750 M 1
FY2028 -KWD 0.938
-KWD 1.578 – -KWD 0.275
250 M 5

النقاط الرئيسية

Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -142.43M
PEG of 0.42 suggests growth is underpriced

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-36.91%
ROIC-19.79%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
0.00
Current Ratio43.76
Interest Coverage0.00

التقييم

P/E Ratio
-9.81
P/B Ratio2.35
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -154.65M
ROE -36.91% ROA -23.37%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -142.43M
ROIC -19.79% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 43.76
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -9.81 P/B Ratio 2.35
P/S Ratio N/A PEG Ratio 0.42
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.52B Enterprise Value 1.34B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 0.0 0.0 0.0
Net Income -154.65M -177.81M -71.90M -29.80M -19.41M
EPS (Diluted) -2.29 -3.66 -1.99 -5.77 -3.89
Gross Profit -59,000.0 0.0 0.0 0.0 0.0
Operating Income -170.60M -192.40M -84.66M -31.48M -18.73M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 661.81M 205.90M 251.64M 114.44M 11.13M
Total Liabilities 15.11M 14.65M 10.48M 166.71M 34.05M
Shareholders' Equity 646.69M 191.26M 241.15M -52.27M -22.93M
Total Debt 0.0 0.0 0.0 0.0 0.0
Cash & Equivalents 172.92M 114.09M 49.30M 87.70M 10.61M
Current Assets 661.39M 205.35M 249.10M 112.81M 11.12M
Current Liabilities 15.11M 14.65M 10.48M 8.07M 5.05M